Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) received positive news when the European Commission approved its oncology drug Kadcyla for the treatment of HER2+advanced breast cancer.

The approval was based on positive results from the phase III study, EMILIA, wherein patients previously treated with Herceptin and a taxane chemotherapy were randomized to receive Kadcyla or a standard treatment, lapatinib and Xeloda.

Data from the study showed that Kadcyla helped extend the life expectancy of patients who were previously treated with lapatanib and Xeloda.

The approval does not surprise us as the Committee for Medicinal Products for Human Use (CHMP) recommended an approval in Sep 2013.

We note that Roche has a solid position in the breast cancer market with drugs like Herceptin, Perjeta and Kadcyla in its kitty for the treatment of patients suffering from HER2+ breast cancer.

The EU approval of the subcutaneous formulation of Herceptin in Sep 2013 was also a boost to Roche’s HER2+ franchise. Moreover, the U.S. Food and Drug Administration (FDA) approved Perjeta for neoadjuvant treatment (use before surgery) in HER2+ early stage breast cancer patients.

We remind investors that Kadcyla was launched in the U.S. in Feb 2013. The EU approval should further strengthen the HER2+ breast cancer franchise at Roche which was up 13% in the first nine months of 2013.

We note that Novartis’ (NVS - Analyst Report) Afinitor is also approved in the U.S. and the EU for the treatment of HER2+ advanced breast cancer in combination with Pfizer’s (PFE - Analyst Report) Aromasin in postmenopausal women, whose disease has returned or progressed even after undergoing treatment with a non-steroidal aromatase inhibitor.

Roche currently carries a Zacks Rank #3 (Hold). Right now, Bayer (BAYRY - Analyst Report) looks attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
FELCOR LODG… FCH 10.48 +3.56%
COVENANT TR… CVTI 12.50 +3.22%
OLD DOMINIO… ODFL 63.47 +1.16%
FIRSTSERVIC… FSRV 56.19 +0.83%
WEBMD HEALT… WBMD 50.31 +0.56%